You are here: Industry Insights > Eleva

News List

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization PharmaSources
October 15, 2024
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.
Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins prnasia
October 13, 2021
Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners.
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H prnasia
September 23, 2021
Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases.
Eleva Drug Candidate Examined for Use in COVID-19 Treatment americanpharmaceuticalreview
June 15, 2020
Eleva is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of COVID-19.
Eleva's Drug Candidate Examined for Use in COVID-19 Treatment americanpharmaceuticalreview
June 10, 2020
Eleva is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of COVID-19.